HRA Pharma has submitted an application to the FDA for the first over-the-counter birth control pill in the U.S., marking a significant moment in reproductive health. The application, which could lead to a decision by mid-2023, is based on years of research demonstrating the safety and effectiveness of self-screening for risks. This move could set a precedent for making contraceptives more accessible, especially to underserved populations.